Daily Archive: November 12, 2011

Nov 12

Post intervention pseudoaneurysm can be treated conservatively

A pseudoaneurysm is a pulsatile hematoma that communicates with an artery through a disruption in the arterial wall. Femoral pseudoaneurysm is a common complication of invasive procedures. It occurs in 0.1% to 0.2% of diagnostic angiograms and 3.5% to 5.5% of interventional procedures. Longer procedures, large-bore catheters, anticoagulation, and a faulty lower site of puncture …

Continue reading »

Nov 12

Heart rate more than 100 at admission a high mortality indicator in AMI

(Dr A.Muralidharan, S.Venkatesan, S.Srikumar, M.Rajendran, N.Viswanathan, A.Rudrappa, Balaji Pandian,P.Arunachalam, V.E.Dhandapani, M.S.Ravi) Age over 75 years; diabetes; Killip class II-IV; heart rate above 100, systolic blood pressure below 100 mmHg; no use of thrombolytic; and complications are significantly associated with higher risk of in-hospital mortality after myocardial infarction. The data will be presented by Dr A.Muralidharan and …

Continue reading »

Nov 12

TCT Update:Longitudinal Stent Compression Rare but Not Deadly

Longitudinal stent compression does occur but is rare says Ajay Kirtane, MD. One can prevent it and safely repair or replace the stent if it does compress. Advanced catheter and stent technology allow deployment into more tortuous arteries with more complex lesions, and the give-and-take sometimes needed to complete the procedure can stress the stent, …

Continue reading »

Nov 12

Cangrelor a Good Bridge for CABG

The novel fast-acting IV antiplatelet drug cangrelor provided an effective bridge for patients on thienopyridine therapy, including clopidogrel, who required bypass surgery, according to results of the late-breaking BRIDGE trial by Dominick J. Agiolillo, MD, PhD, from the University of Florida College of Medicine in Jacksonville. Guidelines recommend discontinuing thienopyridines five to seven days prior …

Continue reading »

Nov 12

Disruptive Valve Technology is the future

The 2 year mortality results of PARTNER cohort B are impressive than the one-year results, and this disruptive percutaneous valve technology will change the way elderly patients are treated, said Dr Michael Mack director of cardiovascular surgery for the Baylor Healthcare System in Dallas. TAVI is more effective and less costly.

Nov 12

DAPT Update

In short term 98% patients stick to dual antiplatelet therapy.  At 30 days not adhering to DAPT is associated with an increased risk (six fold greater)of stent thrombosis. 30 days adherence is important as 80% of the patients are on a second-generation drug-eluting stent, said Dr Roxana Mehran, of Mount Sinai School of Medicine in …

Continue reading »

Nov 12

Facts and Figures in Cardiology

ASD comprises 6-10% of all congenital cardiac defects. Ostiumsecundum ASD accounts for 50-70 % of total patients with ASD’s.